Digital Pathology and Artificial Intelligence Applied to Nonclinical Toxicology Pathology-The Current State, Challenges, and Future Directions.

Gabriele Pohlmeyer-Esch¹, Charles Halsey², Julie Boisclair³, Sripad Ram², Sarah Kirschner-Kitz¹, Brian Knight⁴, Pierre Moulin⁵, Anna-Lena Frisk⁶

¹Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.

²Drug Safety Research and Development, Pfizer Inc, Groton, Connecticut, USA.

³Novartis Pharma AG, Basel, Switzerland.

⁴Boehringer Ingelheim Inc., Ridgefield, Connecticut, USA.

⁵Deciphex Ltd., Dublin, Ireland.

⁶Janssen Pharmaceutica NV, Beerse, Belgium.

PubMed PMC DOI PDF

Abstract

Advancements in digital pathology and artificial intelligence (AI) have enormous transformative potential for nonclinical toxicologic pathology and are already changing the ways in which pathologists work. However, due to the rapid evolution of digital pathology and AI, the toxicologic pathology community would benefit from an update on these advancements, which can be used to aid drug development…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.